The use of prosecution history in post-grant patent proceedings. The Groups are invited to answer the following questions under their national laws.

Size: px
Start display at page:

Download "The use of prosecution history in post-grant patent proceedings. The Groups are invited to answer the following questions under their national laws."

Transcription

1 Question Q229 National Group: Canada Title: The use of prosecution history in post-grant patent proceedings Contributors: ZISCHKA, Matthew SOFIA, Michel HAMILTON, J. Sheldon HARRIS, John ROWAND, Fraser CAWTHORN, Christian CHARI, Santosh SHIPLEY, Kevin COTTRILL, Val BARBIERI, S. Fred WHITE, Bradley Reporter within Working Committee: ZISCHKA, Matthew (Ex-officio) BARBIERI, S. Fred Date: May 17, 2012 Questions The Groups are invited to answer the following questions under their national laws. 1) What types of post-grant proceedings are available in your jurisdiction? Are post-grant proceedings available both at a patent office and at a court? The following post-grant proceedings are available in Canada: (i) Infringement action: a plaintiff may bring a claim for patent infringement by commencing an action in either the Federal Court or a provincial superior court. A defendant to a patent infringement claim may defend on the basis that the patent is invalid. Thus, in an infringement action, a Court may consider both issues of infringement and invalidity. When proceeding in the Federal Court, the defendant may also make a counterclaim for a declaration of invalidity (Patent Act, s. 60(1)). While a finding of invalidity in favour of a defendant is an in personam finding, a declaration of invalidity by the Federal Court operates in rem, and may be registered against the patent. 1

2 (ii) Declaration of non-infringement/invalidity: an interested person may preemptively commence an action in the Federal Court for a declaration of noninfringement (Patent Act, s. 60(2)), and/or a declaration of invalidity (Patent Act, s. 60(1)). (iii) Proceedings under the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations): as a pre-requisite to obtaining regulatory marketing approval for a patented medicine, a generic pharmaceutical producer may allege invalidity and/or non-infringement of certain patents listed by an innovator pharmaceutical producer against the medicine. A subsequent court proceeding brought by the innovator considers whether the allegations of invalidity and/or non-infringement are justified (PM(NOC) Regulations, s. 6). The result of such a proceeding is not determinative of the invalidity of the patents or infringement, and is not binding on the parties private rights of action under the Patent Act, as set out above in items (i) and (ii). As a result, notwithstanding any findings made during PM(NOC) proceedings, parties may assert infringement and/or invalidity in other Court proceedings. (iv) Re-examination: any person, including the patentee, may request reexamination by the Patent Office of any claim of an issued patent (Patent Act, ss ). A request for re-examination may be filed at any time during the term of the patent. To initiate re-examination, a requesting party must submit a request for re-examination, the prescribed fee, prior art (consisting of patents, applications for patents open to public inspection, and printed publications), and an explanation of the pertinence of the prior art and the manner of applying it to the claim for which re-examination is sought. If the request is not made by the patentee, the Patent Office will send a copy to the patentee. A re-examination board established by the Patent Office renders a preliminary decision as to whether the request raises a substantial new question of patentability. If the re-examination board determines that the request does not raise a substantial new question of patentability, the decision of the board is final and not subject to appeal or to review by any court. If the board decides that the request for re-examination does raise a substantial new question of patentability, it notifies the patentee, who then has an opportunity to reply. Although a third party can initiate the re-examination process, once the board determines that a substantial new question is raised, the third party may not participate in the reexamination process (Novozymes v. Genencor International Inc., 2007 FCA 129). During re-examination, the scope of the board s examination is limited to the prior art submitted by the requesting party. The patentee may propose amendments to the claims, including new claims, but the scope of the claim(s) may not be broadened. Furthermore, the re-examination board will not make any changes to the description portion of the patent. The re-examination proceeding must be completed within one year. The re-examination board may issue a certificate canceling a claim determined to be unpatentable, confirming a claim determined to be patentable, or incorporating any proposed amended or new claim determined to be patentable. A decision of a re-examination board may be appealed to the Federal Court by the patentee. (v) Reissue: a patentee may correct a defective patent before the Patent Office (Patent Act, s. 47) by requesting reissue of the patent with correcting amendments. Reissue is available only if an application for reissue is made within 2

3 four years from the date of grant of the patent, and only if the patent is deemed defective or inoperative by reason of insufficient description and specification, or by reason of the patentee s claiming more or less than he had a right to claim as new. To be entitled to reissue, it must be shown that the error which the patentee seeks to correct by reissue arose from inadvertence, accident or mistake. Furthermore, the claims of the reissue application must be directed to the same invention that the patentee attempted to describe and claim in the original application. Upon issue of a new patent, the original patent is surrendered. In addition to the above post-grant proceedings, the following post-grant mechanisms for amending claims are also available in Canada. These post-grant mechanisms are not post-grant proceedings as defined for Q229 as they generally do not require determinations of claim scope. (i) Correction of clerical errors: a patentee or applicant may correct clerical errors in any "instrument of record" in the Patent Office (Patent Act, s. 8) by submitting a request for correction to the Patent Office. A granted patent is an "instrument of record". A clerical error is one that arises in the mechanical process of writing or transcribing (Bayer Aktiengesellschaft v. Canada (Commissioner of Patents) (1980), 53 C.P.R. (2d) 70 (F.C.T.D.) at 73). The significance or importance of the error in the document is not relevant to the determination of whether it is a clerical error. If the Patent Office determines that a clerical error was made, the Patent Office exercises discretion as to whether to correct the clerical error. The Patent Office corrects the clerical error by issuing a Certificate of Correction. (ii) Disclaimers: a patentee may file a disclaimer to amend to narrow the claims of an issued patent, whenever by any mistake, accident or inadvertence, and without any wilful intent to defraud or mislead the public the patentee has made claims that are too broad (Patent Act, s. 48). The patentee thereby disclaims a portion of the monopoly defined by issued claims. Disclaimers are recorded by the Patent Office without examination, and a patentee is not required to explain the mistake, accident or inadvertence justifying a disclaimer. 2) In your country or region, may the prosecution history be taken into account for purposes of interpreting claim scope during post-grant proceedings? In Canada, prosecution history is generally inadmissible in post-grant proceedings for the purpose of construing claims (Free World Trust v. Électro Santé Inc., 2000 SCC 66 at pars ). However, the Patent Office and Courts may use prosecution history in post-grant proceedings for the following limited purposes other than construing the claims. (i) Establish admissions: Courts may allow statements made in the prosecution history to be admitted for the purpose of establishing an admission (Merck Frosst Canada Inc. v. Canada (Minister of Health), 2000 CanLII (FC), aff d 2001 FCA 192). 3

4 (ii) Determine the prior art that was before the Examiner: Canadian case law suggests that the prior art before the Examiner may be relevant at trial. Accordingly, in some instances Courts have held that the prosecution history is relevant to determine what prior art was before the Examiner (Samsonite Corp. v. Holiday Luggage Inc. (1988), 20 C.P.R. (3d) 291 (F.C.)). However, the prosecution history is inadmissible to clarify the meaning of the prior art. Where the prior art that was before the Examiner is known, the prosecution history is irrelevant. (Novartis AG v. Apotex Inc., 2001 FCT 1129, appeal dismissed for mootness, 2002 FCA 440). (iii) Improper prosecution conduct: prosecution history may be admissible in Court proceedings to establish grounds of attack that squarely raise the issue of conduct before the Examiner. (iv) Application for reissue: prosecution history may be admissible in a reissue proceeding before the Patent Office to assess whether the requirements for a reissue application are satisfied. As discussed above, a patentee may correct a defective patent by requesting reissue of the patentthe patentee must establish the amendments sought in a reissue application correct an error in prosecution that arose from inadvertence, accident or mistake (Patent Act, s. 47(1)). Therefore, the alleged error must not have been deliberately caused by the patentee during prosecution through amendments to the claims. For example, the patentee may not reassert claims that were cancelled or withdrawn in the prosecution history, e.g., to overcome prior art. In particular, the patentee may not insert claims broader in scope than claims cancelled or narrowed by the applicant in response to previous rejections by the Examiner. Although amendments to the claims made during prosecution are the most relevant considerations, amendments to the description, e.g., deleting subject matter that is now being claimed in the reissue, may also be relevant. Both amendments made to address prior art and amendments made to address disclosure requirements, e.g., sufficiency or enablement will limit the scope of possible claims that may be pursed in the reissue application. Furthermore, arguments both express and implied made by the patentee during prosecution will also be relevant to assessing whether the error in the resulting patent was inadvertent. The claims of the reissue application must be directed to the same invention that the patentee attempted to describe and claim in the original application (Patent Act, s. 47(1)). Accordingly, the Patent Office assesses the scope of the issued claims and what the patentee intended to protect in the prosecution. The Patent Office then assesses whether the reissue claims are directed to the same invention. In making these assessments, the Patent Office may have regard to statements regarding the nature of the invention or what was intended to be protected by the claims. To counter the Patent Office s reliance on such statements, the patentee may argue that the agent of record erroneously misunderstood the nature of the invention or the patentee s intentions and that the statements previously submitted were based on this erroneous understanding. Nonetheless, statements on the record may become relevant to assessing the intention of the patentee for the purpose of determining whether the requirements for a proper reissue application have been met. (v) Improper reissue: prosecution history may also be admissible in Court proceedings to assess whether a patent was properly reissued by the Patent Office, i.e., whether the requirements for a reissue were satisfied (Burton Parsons Chemicals Inc. v. Hewlett-Packard (Canada) Ltd., [1976] 1 S.C.R. 555). 4

5 (vi) Improper disclaimer: prosecution history may be admissible in Court proceedings to assess the validity of a disclaimer, e.g., whether the requirements for a disclaimer were satisfied. As indicated above, disclaimers are recorded by the Patent Office without examination. However, the validity of a disclaimer may be tested by a Court during subsequent litigation. Furthermore, the Federal Court has held that as a disclaimer is an admission [by the patentee] that the subject matter of the disclaimer is not the proper subject matter of a patent but is open and free to the public generally, invalidity of a disclaimer invalidates the claims which the patentee sought to amend by the disclaimer (Hershkovitz v. Tyco Safety Products Canada Ltd., 2009 FC 256, hereinafter Tyco, at pars. 79, 95-96). Thus, while a Court will normally disregard evidence relating to claim amendments made during prosecution, when a claim amendment by disclaimer has been filed and the validity of that disclaimer is challenged during litigation, the Court will consider both the form and substance of the disclaimer to assess its validity. In particular, the Federal Court has established the following requirements for a valid disclaimer: o the patentee claimed too broadly as a result of a legitimate mistake, accident, or inadvertence (Sanofi-Aventis Canada Inc. v. Hospira Healthcare Corporation, 2009 FC 1077, hereinafter Hospira at pars. 141, 153; Tyco at pars. 74, 91-92); o the patentee filed a disclaimer promptly and diligently upon becoming aware of the mistake, accident, or inadvertence (Tyco at par. 78); o the patentee filed the disclaimer in the prescribed form and manner (Tyco at pars. 75, 80); and o the patentee did not amend claims to introduce inventive features (Tyco at pars. 76, 81-83). When determining the validity of a disclaimer, a Court may, in some circumstances, be willing to look to the prosecution history, particularly when the existence of a legitimate mistake, accident, or inadvertence is at issue. For example, in Tyco the Federal Court stated that a mistake, accident, or inadvertence may be established on the basis that prior art was discovered after issuance of the patent (Tyco at par. 74). Therefore, it appears that to determine whether prior art was discovered after issuance, a Court may need to consider evidence identifying the prior art available to the Examiner during prosecution. In Hospira, the patentee tried to establish a mistake, accident, or inadvertence on the basis that during prosecution the Examiner failed to cite one of the patentee s other patents against the patent at issue, thereby leaving it open to a double patenting attack. While this argument was rejected by the Court, the Court was required to consider the objections made by the Examiner during prosecution (Hospira at par. 144). (vii) Improper correction of a clerical error: prosecution history may be admissible in Court proceedings to assess the validity of a Certificate of Correction correcting a clerical error. A decision by the Patent Office to grant or reject a request to correct a clerical error in a patent is subject to judicial review by a Court. The Court will determine whether the decision of the Patent Office was reasonable, e.g., whether or not the Patent Office s determination of whether or not an error was a clerical error was reasonable (Laboratoires Servier v. Apotex Inc., 2008 FC 825 at pars ). If the answer to question 2 is yes, please answer the following questions: N/A 5

6 a) Please explain the types of prosecution history that may be considered. For example: i. Does applicable prosecution history include amendments, arguments, or both? ii. Could applicable prosecution history include a limiting interpretation that is implied through the applicant s arguments, or would it include only explicit definitional statements? iii. Does applicable prosecution history include only amendments to the claims, or does it also include amendments to any aspect of the disclosure? iv. Does it matter if the amendments and/or arguments are made to overcome prior art versus being made to address sufficiency or some other formal requirement? v. Does it matter if the prosecution history has the effect of broadening the interpretation of the claim, versus narrowing it? b) Does the applicability of prosecution history depend on when the prosecution history occurred? For example, does it matter if a particular statement by an applicant was made during initial examination as opposed to during a later invalidity proceeding? c) Does the applicability of prosecution history depend on the type of post grant proceeding, or on the authority before which the proceeding is held? For example, would prosecution history be more applicable in an infringement action at court than in a post-grant patent office invalidity proceeding? d) Is the applicability of prosecution history limited to infringement proceedings where equivalents are an issue? e) Could prosecution history from a corresponding foreign application be considered in a post-grant proceeding in your jurisdiction? If so, under what circumstances? f) Is the use of prosecution history authorized by statute or by case law in your jurisdiction? g) Explain the policy reasons for considering prosecution history during the claim interpretation process. If the answer to question 2 is no, please answer the following questions: h) Is the disallowance of use of prosecution history mandated by statute or by case law in your jurisdiction? The prohibition against the use of prosecution history for claim construction arises from case law. i) Explain the policy reasons for not considering prosecution history during the claim interpretation process. The Supreme Court of Canada has provided the following policy rationale for excluding the use of prosecution history (referred to as the file wrapper by the 6

7 Court) for claim construction, namely that the test for the inventor s intention is objective, extrinsic evidence would undermine the public notice function of the claims and would increase uncertainty in litigation, and the focus of purposive construction should be on the language of the claims (Free World Trust v. Électro Santé Inc., 2000 SCC 66 at par. 66): [T]hose references to the inventor's intention refer to an objective manifestation of that intent in the patent claims, as interpreted by the person skilled in the art, and do not contemplate extrinsic evidence such as statements or admissions made in the course of patent prosecution. To allow such extrinsic evidence for the purpose of defining the monopoly would undermine the public notice function of the claims, and increase uncertainty as well as fuelling the already overheated engines of patent litigation. The current emphasis on purposive construction, which keeps the focus on the language of the claims, seems also to be inconsistent with opening the pandora's box of file wrapper estoppel. If significant representations are made to the Patent Office touching the scope of the claims, the Patent Office should insist where necessary on an amendment to the claims to reflect the representation. 3) Assuming that at least some countries will consider foreign prosecution history as part of claim interpretation in their jurisdictions, does this have implications for how you would handle prosecution of a patent application in your country? Is this problematic? The possibility that the prosecution history of a Canadian patent may be considered in connection with claim interpretation in another country (i.e., interpretation of claims in a patent based on a corresponding application) may impact the prosecution of a particular patent application in Canada. Where the patent application was drafted by the Canadian patent agent, the Canadian patent agent is in the best position to determine an optimum course of action, in view of the status of prosecution of corresponding applications in other countries. In this case, the Canadian patent agent generally takes care to prosecute the Canadian case in a way that is consistent with the prosecution of the corresponding applications. Where the examination of the corresponding applications is concurrent with the examination of the Canadian application, the Canadian patent agent keeps the foreign associates generally informed of the status of the Canadian patent application. In many cases, prosecution of the corresponding applications is completed before examination of the Canadian application has started, simplifying the Canadian patent agent's task. Where the patent application originated elsewhere, the Canadian patent agent typically relies on the information from an instructing foreign associate to provide instructions that are generally consistent with the prosecution histories of the corresponding applications. In each case, attempting to take the prosecution histories of corresponding (non- Canadian) patent applications into account in the prosecution of the Canadian patent application can be problematic, due to differences in the applicable laws. 4) In your country or region, may a patent be invalidated in post-grant proceedings on the basis of the same prior art which was taken into account by the examiner of the patent office during prosecution of the patent? If so, may the patent be invalidated on the basis of the same prior art and the same argument used by the examiner or may the same prior art only be used if it is shown that there is a new question based on some other teaching or aspect of that prior art? 7

8 Patent validity is assessed de novo by Canadian Courts, and the person challenging the patent is in no way limited by the prior art or arguments taken into account by the Examiner. As discussed above, in re-examination proceedings before the Patent Office, the reexamination board will only consider prior art which raise a substantial new question of patentability, as submitted by the requesting party. However, there is no express requirement that this prior art be different from that considered by the Examiner during prosecution of the patent. Proposals for harmonization The Groups are invited to put forward proposals for the adoption of harmonized rules in relation to the use of prosecution history in post-grant proceedings. More specifically, the Groups are invited to answer the following questions without regard to their national laws: 1) Is harmonization of the applicability of prosecution history in post-grant proceedings desirable? Yes. 2) Is it possible to find a standard for the use of prosecution history that would be universally acceptable? Possibly. 3) Please propose a standard you would consider to be broadly acceptable for a) the types of prosecution history that should be considered, if any; and b) the type of proceeding and circumstances in which it should be considered. Harmonizing the effect of prosecution history in post-grant proceedings across all jurisdictions may be impractical, and may offer limited benefit without more generally harmonizing laws governing claim interpretation/construction and validity. However, it may be possible and desirable to harmonize the inbound effect of foreign prosecution history in domestic post-grant proceedings. Preferably, a standard that prohibits consideration of foreign prosecution history in any post-grant proceeding should be adopted in all jurisdictions. From the perspective of an applicant/agent within a particular jurisdiction, this standard would eliminate uncertainty in assessing extra-territorial effect of steps taken in domestic prosecution namely, there would be no extra-territorial effect. This standard would allow applicants/agents to prosecute applications with greater candour, and without being burdened by consideration of foreign law in multiple jurisdictions having a variety of post-grant proceedings, and a variety of laws governing such proceedings. This standard would also eliminate the risk of deleterious effect of imperfect translation of any prosecution history in post-grant proceedings. In alternative, a standard that uniformly permits consideration of foreign prosecution history for limited purposes in all jurisdictions, such as establishing admissions, or impeaching credibility on the basis of prior inconsistent statements would also be desirable. Under this standard, statements made in foreign prosecution would not give rise to legal estoppels or questions of conduct, but may undermine positions on claim scope taken by the patentee in post-grant proceedings. This standard would promote consistency between statements of fact made during prosecution and in post-grant 8

9 proceedings, without burdening applicants/agents with consideration of foreign law during prosecution. In the further alternative, a standard that uniformly permits consideration of foreign prosecution history for any purpose in all jurisdictions, though less desirable, would still promote clarity and predictability in extraterritorial effect of domestic prosecution namely, there may be extraterritorial effect in all foreign jurisdictions. 9

2016 Study Question (Patents)

2016 Study Question (Patents) 2016 Study Question (Patents) Submission date: 3rd May 2016 Sarah MATHESON, Reporter General John OSHA and Anne Marie VERSCHUUR, Deputy Reporters General Yusuke INUI, Ari LAAKKONEN and Ralph NACK, Assistants

More information

POST-GRANT AMENDMENT JOHN RICHARDS

POST-GRANT AMENDMENT JOHN RICHARDS 23 rd Annual Fordham Intellectual Property Law & Policy Conference Cambridge, April 8-9, 2015 POST-GRANT AMENDMENT JOHN RICHARDS The Problem There is a real life problem in that when filing a patent application

More information

Second medical use or indication claims

Second medical use or indication claims Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Canada Second medical use or indication claims Matthew ZISCHKA Santosh CHARI Carol HITCHMANN Roseanne CALDWELL Charles

More information

Examination Practice Respecting Purposive Construction PN

Examination Practice Respecting Purposive Construction PN 5 Whirlpool at paragraph 49 1 March 8, 2013 To all examiners: Examination Practice Respecting Purposive Construction PN2013-02 In Canada (Attorney General) v Amazon.com Inc., 2011 FCA 328 [Amazon FCA],

More information

The use of prosecution history in post-grant patent proceedings

The use of prosecution history in post-grant patent proceedings Question Q229 National Group: United States Title: The use of prosecution history in post-grant patent proceedings Contributors: ADAMO, Kenneth R. ARROYO, Blas ASHER, Robert BAIN, Joseph MEUNIER, Andrew

More information

AIPPI Study Question - Patentability of computer implemented inventions

AIPPI Study Question - Patentability of computer implemented inventions Study Question Submission date: June 19, 2017 Sarah MATHESON, Reporter General Jonathan P. OSHA and Anne Marie VERSCHUUR, Deputy Reporters General Yusuke INUI, Ari LAAKKONEN and Ralph NACK, Assistants

More information

OLIVE & OLIVE, P.A. INTELLECTUAL PROPERTY LAW

OLIVE & OLIVE, P.A. INTELLECTUAL PROPERTY LAW OLIVE & OLIVE, P.A. INTELLECTUAL PROPERTY LAW Since 1957 500 MEMORIAL ST. POST OFFICE BOX 2049 DURHAM, NORTH CAROLINA 27702-2049 (919) 683-5514 GENERAL RULES PERTAINING TO PATENT INFRINGEMENT Patent infringement

More information

INTELLECTUAL PROPERTY LAWS AMENDMENT (RAISING THE BAR ACT) 2012

INTELLECTUAL PROPERTY LAWS AMENDMENT (RAISING THE BAR ACT) 2012 INTELLECTUAL PROPERTY LAWS AMENDMENT (RAISING THE BAR ACT) 2012 AUTHOR: MICHAEL CAINE - PARTNER, DAVIES COLLISON CAVE Michael is a fellow and council member of the Institute of Patent and Trade Mark Attorneys

More information

Indexed As: Dow Chemical Co. et al. v. Nova Chemicals Corp. Federal Court O'Keefe, J. September 5, 2014.

Indexed As: Dow Chemical Co. et al. v. Nova Chemicals Corp. Federal Court O'Keefe, J. September 5, 2014. The Dow Chemical Company, Dow Global Technologies Inc. and Dow Chemical Canada ULC (plaintiffs) v. Nova Chemicals Corporation (defendant) (T-2051-10; 2014 FC 844) Indexed As: Dow Chemical Co. et al. v.

More information

Title: The patentability criterion of inventive step / non-obviousness

Title: The patentability criterion of inventive step / non-obviousness Question Q217 National Group: Canada Title: The patentability criterion of inventive step / non-obviousness Contributors: Reporter within Working Committee: France Côté (chair) Philip Mendes Da Costa Don

More information

Considerations for the United States

Considerations for the United States Considerations for the United States Speaker: Donald G. Lewis US Patent Attorney California Law Firm Leahy-Smith America Invents Act First Inventor to file, with grace period Derivation Actions Prior user

More information

US reissue procedure can fix failure to include dependent claims

US reissue procedure can fix failure to include dependent claims US reissue procedure can fix failure to include dependent claims Journal of Intellectual Property Law & Practice, 2011 Author(s): Charles R. Macedo In re Tanaka, No. 2010-1262, US Court of Appeals for

More information

CANADA: INTERNATIONAL TREATIES AND THE PROMISE OF THE PATENT

CANADA: INTERNATIONAL TREATIES AND THE PROMISE OF THE PATENT CANADA: INTERNATIONAL TREATIES AND THE PROMISE OF THE PATENT By Thomas Kurys July 24, 2017 www.dlapiper.com DLA Piper Canada LLP July 24, 2017 0 To Be Discussed 1 Comprehensive Economic and Trade Agreement

More information

The use of prosecution history in post-grant patent proceedings

The use of prosecution history in post-grant patent proceedings Question Q229 National Group: Netherlands Title: The use of prosecution history in post-grant patent proceedings Contributors: Reporter within Working Committee: John ALLEN (Chair), Bas Berghuis van Woortman,

More information

AUSTRALIA Patents Act 1990 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017

AUSTRALIA Patents Act 1990 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017 AUSTRALIA Patents Act 1990 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017 TABLE OF CONTENTS Chapter 1. Introductory 1 Short title 2 Commencement

More information

Are Your Chinese Patents At Risk?

Are Your Chinese Patents At Risk? October 2004 Are Your Chinese Patents At Risk? Viagra, the anti-impotence drug made by Pfizer, generated about $1.7 billion in worldwide sales last year. Viagra s active ingredient is a substance called

More information

POST-GRANT REVIEW UNDER THE AMERICA INVENTS ACT GERARD F. DIEBNER TANNENBAUM, HELPERN, SYRACUSE & HIRSCHTRITT LLP

POST-GRANT REVIEW UNDER THE AMERICA INVENTS ACT GERARD F. DIEBNER TANNENBAUM, HELPERN, SYRACUSE & HIRSCHTRITT LLP POST-GRANT REVIEW UNDER THE AMERICA INVENTS ACT GERARD F. DIEBNER TANNENBAUM, HELPERN, SYRACUSE & HIRSCHTRITT LLP TABLE OF CONTENTS Page I. Introduction... 1 II. Post-Grant Review Proceedings... 1 A. Inter-Partes

More information

Correction of Patents

Correction of Patents Correction of Patents Seema Mehta Kelly McKinney November 9, 2011 Overview: Three Options Certificate of Correction Reissue Reexamination in view of the America Invents Act (AIA) Certificate of Correction

More information

Are the Patented Medicines (Notice of Compliance) Regulations Working?

Are the Patented Medicines (Notice of Compliance) Regulations Working? Are the Patented Medicines (Notice of Compliance) Regulations Working? Edward Hore Hazzard & Hore 141 Adelaide Street West, Suite 1002 Toronto, ON M5H 3L5 (416) 868-1340 edhore@hazzardandhore.com March

More information

The use of prosecution history in post-grant patent proceedings. Maria CRUZ GARCIA, Isabel FRANCO, João JORGE, Teresa SILVA GARCIA

The use of prosecution history in post-grant patent proceedings. Maria CRUZ GARCIA, Isabel FRANCO, João JORGE, Teresa SILVA GARCIA Question Q229 National Group: Title: Portugal The use of prosecution history in post-grant patent proceedings Contributors: Filipe BAPTISTA, Maria CRUZ GARCIA, Isabel FRANCO, João JORGE, Teresa SILVA GARCIA

More information

2016 Study Question (Patents)

2016 Study Question (Patents) 2016 Study Question (Patents) Submission date: 25th May 2016 Sarah MATHESON, Reporter General John OSHA and Anne Marie VERSCHUUR, Deputy Reporters General Yusuke INUI, Ari LAAKKONEN and Ralph NACK, Assistants

More information

These materials are public information and have been prepared solely for educational and entertainment purposes to contribute to the understanding of

These materials are public information and have been prepared solely for educational and entertainment purposes to contribute to the understanding of May 14, 2013 These materials are public information and have been prepared solely for educational and entertainment purposes to contribute to the understanding of U.S. intellectual property law. These

More information

Early Resolution Mechanism for Patent Disputes Regarding Approved Drug Products - Canada

Early Resolution Mechanism for Patent Disputes Regarding Approved Drug Products - Canada Early Resolution Mechanism for Patent Disputes Regarding Approved Drug Products - Canada Pharma Workshop 4 AIPPI Toronto September 16, 2014 Warren Sprigings Direct Dial: +1-416-777-2273 warren@sprigings.com

More information

America Invents Act (AIA) Post-Grant Proceedings

America Invents Act (AIA) Post-Grant Proceedings America Invents Act (AIA) Post-Grant Proceedings Various Post-Grant Proceedings under AIA Ex parte reexamination Modified by AIA Sec. 6(h)(2) Continue to be available under AIA Inter partes reexamination

More information

America Invents Act: Patent Reform

America Invents Act: Patent Reform America Invents Act: Patent Reform Gunnar Leinberg, Nicholas Gallo, and Gerald Gibbs LeClairRyan December 2011 gunnar.leinberg@leclairryan.com; nicholas.gallo@leclaairryan.com; and gerald.gibbs@leclairryan.com

More information

Rules for the Implementation of the Patent Law of the People's Republic of China

Rules for the Implementation of the Patent Law of the People's Republic of China Rules for the Implementation of the Patent Law of the People's Republic of China (Promulgated by Decree No. 306 of the State Council of the People's Republic of China on June 15, 2001, and revised according

More information

50 Victoria St. confirmation by mail Gatineau, Quebec K1A 0C9

50 Victoria St. confirmation by mail Gatineau, Quebec K1A 0C9 - 1 - September 8, 2017 The Commissioner of Patents, submitted electronically 50 Victoria St. confirmation by mail Gatineau, Quebec K1A 0C9 Dear Commissioner: Attn: A. Lajoie Re: Proposed Patent Rules

More information

America Invents Act: Patent Reform

America Invents Act: Patent Reform America Invents Act: Patent Reform Gunnar Leinberg, Nicholas Gallo, and Gerald F. Gibbs, Jr. LeClairRyan January 4 th 2012 gunnar.leinberg@leclairryan.com; nicholas.gallo@leclaairryan.com; and gerald.gibbs@leclairryan.com

More information

Compilation date: 24 February Includes amendments up to: Act No. 61, Registered: 27 February 2017

Compilation date: 24 February Includes amendments up to: Act No. 61, Registered: 27 February 2017 Patents Act 1990 No. 83, 1990 Compilation No. 41 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017 This compilation includes commenced amendments

More information

Issues of Patent Drafting in Canadian Patent Law: A Unique Paradigm. By Livia Aumand & John Norman. Gowling WLG (Canada) LLP

Issues of Patent Drafting in Canadian Patent Law: A Unique Paradigm. By Livia Aumand & John Norman. Gowling WLG (Canada) LLP Issues of Patent Drafting in Canadian Patent Law: A Unique Paradigm By Livia Aumand & John Norman Gowling WLG (Canada) LLP In the past 10-15 years, there has been an evolution in Canadian patent law that

More information

Chemical Patent Practice. Course Syllabus

Chemical Patent Practice. Course Syllabus Chemical Patent Practice Course Syllabus I. INTRODUCTION TO CHEMICAL PATENT PRACTICE: SETTING THE STAGE FOR DISCUSSING STRATEGIES FOR REDUCING RISK OF UNENFORCEABILITY AND ENHANCING CHANCES OF INFRINGEMENT,

More information

Chapter 1400 Correction of Patents

Chapter 1400 Correction of Patents Chapter 1400 Correction of Patents 1400.01 Introduction 1401 Reissue 1402 Grounds for Filing 1403 Diligence in Filing 1404 Submission of Papers Where Reissue Patent Is in Litigation 1405 Reissue and Patent

More information

HOW TO EVALUATE WHEN A REISSUE VIOLATES THE RECAPTURE RULE:

HOW TO EVALUATE WHEN A REISSUE VIOLATES THE RECAPTURE RULE: HOW TO EVALUATE WHEN A REISSUE VIOLATES THE RECAPTURE RULE: #8 Collected Case Law, Rules, and MPEP Materials 2004 Kagan Binder, PLLC How to Evaluate When a Reissue violates the Recapture Rule: Collected

More information

Questionnaire. Apotex-Inc. v Sanofi-Aventis

Questionnaire. Apotex-Inc. v Sanofi-Aventis Questionnaire Apotex-Inc. v Sanofi-Aventis 1. Introduction In Apotex Inc. v Sanofi-Aventis, the Supreme Court of Canada has granted leave to Apotex Inc to appeal the validity of a Canadian pharmaceutical

More information

How To Fix The Amendment Fallacy

How To Fix The Amendment Fallacy Intellectual Property How To Fix The Amendment Fallacy This article was originally published in Managing Intellectual Property on April 28, 2014 by Patrick Doody Patrick A. Doody Intellectual Property

More information

USPTO Post Grant Trial Practice

USPTO Post Grant Trial Practice Bill Meunier, Member Michael Newman, Member Peter Cuomo, Of Counsel July 18, 2016 Basics: Nomenclature "IPRs" = Inter partes review proceedings "PGRs" = Post-grant review proceedings "CBMs" = Post-grant

More information

SEC. 6. AIA: POST-GRANT REVIEW PROCEEDINGS

SEC. 6. AIA: POST-GRANT REVIEW PROCEEDINGS SEC. 6. AIA: POST-GRANT REVIEW PROCEEDINGS (a) INTER PARTES REVIEW. Chapter 31 of title 35, United States Code, is amended to read as follows: Sec. 3 1 1. I n t e r p a r t e s r e v i e w. 3 1 2. P e

More information

Presented by Karl Fink, Nikki Little, and Tim Maloney. AIPLA Corporate Practice Committee Breakfast Meeting May 18, 2016

Presented by Karl Fink, Nikki Little, and Tim Maloney. AIPLA Corporate Practice Committee Breakfast Meeting May 18, 2016 Presented by Karl Fink, Nikki Little, and Tim Maloney AIPLA Corporate Practice Committee Breakfast Meeting May 18, 2016 2016 Fitch, Even, Tabin & Flannery LLP Overview Introduction to Proceedings Challenger

More information

Accelerated Examination. Presented by Hans Troesch, Principal Fish & Richardson P.C. March 2, 2010

Accelerated Examination. Presented by Hans Troesch, Principal Fish & Richardson P.C. March 2, 2010 Accelerated Examination Presented by Hans Troesch, Principal Fish & Richardson P.C. March 2, 2010 Overview The Basics Petition for accelerated examination Pre-examination search Examination Support Document

More information

PCT/GL/ISPE/1 Page 194 PART VIII CLERICAL AND ADMINISTRATIVE PROCEDURES. Chapter 22 Clerical and Administrative Procedures

PCT/GL/ISPE/1 Page 194 PART VIII CLERICAL AND ADMINISTRATIVE PROCEDURES. Chapter 22 Clerical and Administrative Procedures Page 194 PART VIII CLERICAL AND ADMINISTRATIVE PROCEDURES Chapter 22 Clerical and Administrative Procedures Receipt of the Demand Article 31(6)(a) 22.01 The International Preliminary Examining Authority

More information

Third Party Observations, Oppositions & Invalidation Trials of Patents in Japan

Third Party Observations, Oppositions & Invalidation Trials of Patents in Japan Third Party Observations, Oppositions & Invalidation Trials of Patents in Japan Aki Ryuka Japanese Patent Attorney Attorney at Law, California, U.S.A. October 12, 2015 This information is provided for

More information

UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA PATENT CASE SCHEDULE. Answer or Other Response to Complaint 5 weeks

UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA PATENT CASE SCHEDULE. Answer or Other Response to Complaint 5 weeks UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA PATENT CASE SCHEDULE Event Service of Complaint Scheduled Time Total Time After Complaint Answer or Other Response to Complaint 5 weeks Initial

More information

Ordinary or Extraordinary: The NOC Regulations

Ordinary or Extraordinary: The NOC Regulations Ordinary or Extraordinary: The NOC Regulations Bill Richardson Partner McCarthy Tétrault LLP (Toronto) Co-authors: Jacob Glick, Meighan Leon and Tamara Ramsey Associates McCarthy Tétrault LLP March 29-30,

More information

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE. Plaintiffs, Civil Action No RGA

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE. Plaintiffs, Civil Action No RGA IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE SANOFI-AVENTIS U.S. LLC, SANOFI A VENTIS DEUTSCHLAND GMBH, and SANOFI WINTHROP INDUSTRIE, v. Plaintiffs, Civil Action No. 16-812-RGA MERCK

More information

Patent Procedures Amendment Act of 2016

Patent Procedures Amendment Act of 2016 Patent Procedures Amendment Act of 2016 Harold C. Wegner * Foreword, Lessons from Japan 2 The Proposed Legislation 4 Sec. 1. Short Title; Table Of Contents 5 Sec. 101. Reissue Proceedings. 5 Sec. 102.

More information

America Invents Act (AIA) Post-Grant Proceedings. Jeffrey S. Bergman Kevin Kuelbs Laura Witbeck

America Invents Act (AIA) Post-Grant Proceedings. Jeffrey S. Bergman Kevin Kuelbs Laura Witbeck America Invents Act (AIA) Post-Grant Proceedings Jeffrey S. Bergman Kevin Kuelbs Laura Witbeck What is included in Post-Grant Reform in the U.S.? Some current procedures are modified and some new ones

More information

Patent Resources Group Federal Circuit Law Course Syllabus

Patent Resources Group Federal Circuit Law Course Syllabus I. Novelty and Loss of Right to a Patent II. III. IV. A. Anticipation 1. Court Review of PTO Decisions 2. Claim Construction 3. Anticipation Shown Through Inherency 4. Single Reference Rule Incorporation

More information

The Patents Act 1977 (as amended)

The Patents Act 1977 (as amended) The Patents Act 1977 (as amended) An unofficial consolidation produced by Patents Legal Section 17 December 2007 UK Intellectual Property Office is an operating name of the Patent Office 1 Note to users

More information

Patent Cooperation Treaty

Patent Cooperation Treaty Patent Cooperation Treaty Done at Washington on June 19, 1970, amended on September 28, 1979, modified on February 3, 1984, and October 3, 2001 (as in force from April 1, 2002) NTRODUCTORY PROVISIONS Article

More information

BELIZE PATENTS ACT CHAPTER 253 REVISED EDITION 2003 SHOWING THE SUBSIDIARY LAWS AS AT 31ST MAY, 2003

BELIZE PATENTS ACT CHAPTER 253 REVISED EDITION 2003 SHOWING THE SUBSIDIARY LAWS AS AT 31ST MAY, 2003 BELIZE PATENTS ACT CHAPTER 253 REVISED EDITION 2003 SHOWING THE SUBSIDIARY LAWS AS AT 31ST MAY, 2003 This is a revised edition of the Subsidiary Laws, prepared by the Law Revision Commissioner under the

More information

Patent Resources Group. Chemical Patent Practice. Course Syllabus

Patent Resources Group. Chemical Patent Practice. Course Syllabus Patent Resources Group Chemical Patent Practice Course Syllabus I. INTRODUCTION II. USER GUIDE: Overview of America Invents Act Changes with Respect to Prior Art III. DRAFTING CHEMICAL CLAIMS AND SPECIFICATION

More information

Title: The patentability criterion of inventive step / non-obviousness

Title: The patentability criterion of inventive step / non-obviousness Question Q217 National Group: China Title: The patentability criterion of inventive step / non-obviousness Contributors: [Heather Lin, Gavin Jia, Shengguang Zhong, Richard Wang, Jonathan Miao, Wilson Zhang,

More information

5 Multiple Protection of Inventions

5 Multiple Protection of Inventions 5 Multiple Protection of Inventions From the perspective of helping front runners efforts to obtain multiple protection rights and achieving international harmonization of systems, research studies were

More information

Fordham International Law Journal

Fordham International Law Journal Fordham International Law Journal Volume 11, Issue 3 1987 Article 2 The Amended Canadian Patent Act: General Amendments and Pharmaceutical Patents Compulsory Licensing Provisions Milan Chromecek Copyright

More information

Delain Law Office, PLLC

Delain Law Office, PLLC Delain Law Office, PLLC Patent Prosecution and Appeal Tips From PTO Day, December 5, 2005 Nancy Baum Delain, Esq. Registered Patent Attorney Delain Law Office, PLLC Clifton Park, NY http://www.ipattorneyfirm.com

More information

CHINA Patent Regulations as amended on June 15, 2001 ENTRY INTO FORCE: July 1, 2001

CHINA Patent Regulations as amended on June 15, 2001 ENTRY INTO FORCE: July 1, 2001 CHINA Patent Regulations as amended on June 15, 2001 ENTRY INTO FORCE: July 1, 2001 TABLE OF CONTENTS Chapter 1 General Provisions Rule 1 Rule 2 Rule 3 Rule 4 Rule 5 Rule 6 Rule 7 Rule 8 Rule 9 Rule 10

More information

Reproduced from Statutes of the Republic of Korea Copyright C 1997 by the Korea Legislation Research Institute, Seoul, Korea PATENT ACT

Reproduced from Statutes of the Republic of Korea Copyright C 1997 by the Korea Legislation Research Institute, Seoul, Korea PATENT ACT Reproduced from Statutes of the Republic of Korea Copyright C 1997 by the Korea Legislation Research Institute, Seoul, Korea PATENT ACT Note: The Acts and subordinate statutes translated into English herein

More information

Should Patent Prosecution Bars Apply To Interference Counsel? 1. Charles L. Gholz 2. and. Parag Shekher 3

Should Patent Prosecution Bars Apply To Interference Counsel? 1. Charles L. Gholz 2. and. Parag Shekher 3 Should Patent Prosecution Bars Apply To Interference Counsel? 1 By Charles L. Gholz 2 and Parag Shekher 3 Introduction The Federal Circuit stated that it granted a rare petition for a writ of mandamus

More information

UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT NUPLA CORPORATION, Plaintiff-Appellant, IXL MANUFACTURING COMPANY INC.

UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT NUPLA CORPORATION, Plaintiff-Appellant, IXL MANUFACTURING COMPANY INC. UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT 96-1388 NUPLA CORPORATION, Plaintiff-Appellant, v. IXL MANUFACTURING COMPANY INC., Defendant-Appellee. Kamran Fattahi, Kelly, Bauersfeld & Lowry,

More information

United States Court of Appeals for the Federal Circuit

United States Court of Appeals for the Federal Circuit United States Court of Appeals for the Federal Circuit 01-1439 (Serial no. 08/601,101) IN RE MICHAEL P. DOYLE Meredith Martin Addy, Brinks Hofer Gilson & Lione, of Chicago, Illinois, argued for appellant.

More information

CASE NO: 657/95. In the matter between: and CHEMICAL, MINING AND INDUSTRIAL

CASE NO: 657/95. In the matter between: and CHEMICAL, MINING AND INDUSTRIAL CASE NO: 657/95 In the matter between: JOHN PAUL McKELVEY NEW CONCEPT MINING (PTY) LTD CERAMIC LININGS (PTY) LTD 1st Appellant 2nd Appellant 3rd Appellant and DETON ENGINEERING (PTY) LTD CHEMICAL, MINING

More information

Freedom to Operate and Selected Issues

Freedom to Operate and Selected Issues Freedom to Operate and Selected Issues March 9, 2010 Presented by: Cary A. Levitt My principal business consists of giving commercial value to the brilliant, but misdirected, ideas of others... Accordingly,

More information

CORRECTION OF ISSUED PATENTS

CORRECTION OF ISSUED PATENTS CORRECTION OF ISSUED PATENTS 2012 IP Summer Seminar Peter Corless Partner pcorless@edwardswildman.com July 2012 2012 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Types of Correction Traditional

More information

THE SUPREME COURT'S DECISION IN

THE SUPREME COURT'S DECISION IN THE SUPREME COURT'S DECISION IN June 20, 2002 On May 28, the U.S. Supreme Court issued its longawaited decision in Festo Corporation v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 1 vacating the landmark

More information

AIA Post-Grant Implementation Begins - Is Your Business Strategy Aligned? August 27, A Web conference hosted by Foley & Lardner LLP

AIA Post-Grant Implementation Begins - Is Your Business Strategy Aligned? August 27, A Web conference hosted by Foley & Lardner LLP AIA Post-Grant Implementation Begins - Is Your Business Strategy Aligned? August 27, 2012 A Web conference hosted by Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome

More information

COMPARATIVE STUDY REPORT REQUIREMENTS FOR DISCLOSURE AND CLAIMS - 1 -

COMPARATIVE STUDY REPORT REQUIREMENTS FOR DISCLOSURE AND CLAIMS - 1 - COMPARATIVE STUDY REPORT ON REQUIREMENTS FOR DISCLOSURE AND CLAIMS - 1 - CONTENTS Comparison Outline (i) Legal bases concerning the requirements for disclosure and claims (1) Relevant provisions in laws

More information

Understanding and Applying the CREATE Act in Collaborations

Understanding and Applying the CREATE Act in Collaborations Page 1 Understanding and Applying the CREATE Act in Collaborations, is an assistant professor at Emory University School of Law in Atlanta, Georgia. The Cooperative Research and Technology Enhancement

More information

America Invents Act of 2011 Part 1: Impact on Litigation Strategy Part 2: Strategic Considerations of the FTF Transition

America Invents Act of 2011 Part 1: Impact on Litigation Strategy Part 2: Strategic Considerations of the FTF Transition America Invents Act of 2011 Part 1: Impact on Litigation Strategy Part 2: Strategic Considerations of the FTF Transition Dave Cochran Jones Day Cleveland December 6, 2012 Part 1: Impact on Litigation Strategy

More information

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:

Questionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of: Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Australia... Office: IP Australia... Person to be contacted: Name:

More information

2012 Winston & Strawn LLP

2012 Winston & Strawn LLP 2012 Winston & Strawn LLP How the America Invents Act s Post-Issuance Proceedings Influence Litigation Strategy Brought to you by Winston & Strawn s Intellectual Property practice group 2012 Winston &

More information

America Invents Act: The Practical Effects of the New USPTO Post-Grant Proceedings

America Invents Act: The Practical Effects of the New USPTO Post-Grant Proceedings PRESENTATION TITLE America Invents Act: The Practical Effects of the New USPTO Post-Grant Proceedings Wab Kadaba February 8, 2012 1 America Invents Act of 2011 Signed by President Obama on Sept. 16, 2011

More information

Prosecuting an Israel Patent Application and Beyond

Prosecuting an Israel Patent Application and Beyond page 1 of 11 Prosecuting an Israel Patent Application and Beyond Updated July 2017 LIST OF CONTENTS 1. General Information (page 2) a. Language b. Conventions c. Obtaining a filing date and number d. Excess

More information

America Invents Act Implementing Rules. September 2012

America Invents Act Implementing Rules. September 2012 America Invents Act Implementing Rules September 2012 AIA Rules (Part 2) Post Grant Review Inter Partes Review Section 18 Proceedings Derivation Proceedings Practice before the PTAB 2 Post Grant Review

More information

Patent Cooperation Treaty

Patent Cooperation Treaty Patent Cooperation Treaty Done at Washington on June 19, 1970, amended on September 28, 1979, modified on February 3, 1984, and October 3, 2001 (as in force from April 1, 2002) TABLE OF CONTENTS* Preamble

More information

Korean Intellectual Property Office

Korean Intellectual Property Office www.kipo.go.kr 2007 Korean Intellectual Property Office INDUSTRIAL PROPERTY LAWS OF THE REPUBLIC OF KOREA 2007 INDUSTRIAL PROPERTY LAWS OF THE REPUBLIC OF KOREA 2007 PATENT ACT 1 UTILITY MODEL ACT 127

More information

Post-Grant Proceedings at the Patent Office After Passage of the America Invents Act

Post-Grant Proceedings at the Patent Office After Passage of the America Invents Act Post-Grant Proceedings at the Patent Office After Passage of the America Invents Act Patrick A. Doody, Partner Northern Virginia Office America Invents Act (AIA) S 23 Senate Verison Passed the Senate in

More information

Code of Procedure for Matters under the Personal Health

Code of Procedure for Matters under the Personal Health HEALTH MARCH 2017 Code of Procedure for Matters under the Personal Health Information Protection Act, 2004 CONTENTS PART I INTRODUCTION...1 1. Application...1 2. Purpose and Interpretation...1 3. Definitions...2

More information

Paper Entered: September 21, 2016 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

Paper Entered: September 21, 2016 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Trials@uspto.gov Paper 12 571-272-7822 Entered: September 21, 2016 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD SMITH & NEPHEW, INC. and ARTHROCARE CORP., Petitioner,

More information

Dawn of an English Doctrine of Equivalents: immaterial variants infringe

Dawn of an English Doctrine of Equivalents: immaterial variants infringe Dawn of an English Doctrine of Equivalents: immaterial variants infringe November 2017 The Supreme Court reinvents patent infringement The Supreme Court s landmark judgment in Actavis v Eli Lilly is a

More information

Claims and Determining Scope of Protection

Claims and Determining Scope of Protection Introduction 2014 APAA Patents Committee Questionnaire Claims and Determining Scope of Protection for Taiwan Group Many practitioners and users of the patent system believe that it is a fairly universal

More information

United States Patent and Trademark Office. Patent Trial and Appeal Board

United States Patent and Trademark Office. Patent Trial and Appeal Board United States Patent and Trademark Office Patent Trial and Appeal Board PTAB Organization Statutory Members of the Board The Board is created by statute (35 U.S.C. 6). 35 U.S.C. 6(a) provides: There shall

More information

Law on Trademarks and Indications of Geographical Origin

Law on Trademarks and Indications of Geographical Origin Law on Trademarks and Indications of Geographical Origin Adopted: Entered into Force: Published: 16.06.1999 15.07.1999 Vēstnesis, 01.07.1999, Nr. 216 With the changes of 08.11.2001 Chapter I General Provisions

More information

UNITED STATES PATENT AND TRADEMARK OFFICE. REPORT TO CONGRESS on INTER PARTES REEXAMINATION. Executive Summary

UNITED STATES PATENT AND TRADEMARK OFFICE. REPORT TO CONGRESS on INTER PARTES REEXAMINATION. Executive Summary UNITED STATES PATENT AND TRADEMARK OFFICE REPORT TO CONGRESS on INTER PARTES REEXAMINATION Executive Summary The United States Patent and Trademark Office (USPTO) examines patent applications and grants

More information

QUESTION PAPER REFERENCE: FC3 PERCENTAGE MARK AWARDED: 59% six months after the publication of European search report

QUESTION PAPER REFERENCE: FC3 PERCENTAGE MARK AWARDED: 59% six months after the publication of European search report QUESTION PAPER REFERENCE: FC3 PERCENTAGE MARK AWARDED: 59% Question 1 a) Deadline for validating granted European patent in EPC six months after the publication of European search report 0 b) i) Germany

More information

Questionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal

Questionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal National Group: Hungarian Title: Reporter: Contributors: Questionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal Dr. PETHŐ, Árpád Dr. PETHŐ, Árpád, MOLNÁR,

More information

GLOSSARY of patent related terms in the FOUR OFFICE STATISTICS REPORT 2010 EDITION

GLOSSARY of patent related terms in the FOUR OFFICE STATISTICS REPORT 2010 EDITION GLOSSARY of patent related terms in the FOUR OFFICE STATISTICS RRT 2010 EDITION Disclaimer: The explanations in this glossary are given in order to help readers of the Four Office Statistics Report in

More information

POST GRANT REVIEW PROCEEDINGS IN THE PTO STEPHEN G. KUNIN PARTNER

POST GRANT REVIEW PROCEEDINGS IN THE PTO STEPHEN G. KUNIN PARTNER POST GRANT REVIEW PROCEEDINGS IN THE PTO STEPHEN G. KUNIN PARTNER PATENT TRIAL AND APPEAL BOARD (PTAB) COMPOSITION DIRECTOR DEPUTY DIRECTOR COMMISSIONER FOR PATENTS COMMISSIONER FOR TRADEMARKS APJ 2 PATENT

More information

DEVELOPMENTS IN CLAIM CONSTRUCTION

DEVELOPMENTS IN CLAIM CONSTRUCTION The University of Texas School of Law 16th ANNUAL ADVANCED PATENT LAW INSTITUTE DEVELOPMENTS IN CLAIM CONSTRUCTION October 27-28, 2011 Austin, Texas Kenneth R. Adamo* Kirkland & Ellis LLP 300 N. LaSalle

More information

PATENTS ACT NO. 57 OF 1978 [ASSENTED TO 26 APRIL, 1978] [DATE OF COMMENCEMENT: 1 JANUARY, 1979]

PATENTS ACT NO. 57 OF 1978 [ASSENTED TO 26 APRIL, 1978] [DATE OF COMMENCEMENT: 1 JANUARY, 1979] PATENTS ACT NO. 57 OF 1978 [ASSENTED TO 26 APRIL, 1978] [DATE OF COMMENCEMENT: 1 JANUARY, 1979] (Unless otherwise indicated) (English text signed by the State President) as amended by Patents Amendment

More information

Inequitable Conduct Judicial Developments

Inequitable Conduct Judicial Developments Inequitable Conduct Judicial Developments Duke Patent Law Institute May 16, 2013 Presented by Tom Irving Copyright Finnegan 2013 Disclaimer These materials are public information and have been prepared

More information

National Patent Board Non-Binding Arbitration Rules TABLE OF CONTENTS

National Patent Board Non-Binding Arbitration Rules TABLE OF CONTENTS National Patent Board Non-Binding Arbitration Rules Rules Amended and Effective June 1, 2014 TABLE OF CONTENTS Important Notice...3 Introduction...3 Standard Clause...3 Submission Agreement...3 Administrative

More information

Singapore Patents Rules as amended by S 739 of 2014 ENTRY INTO FORCE: Nov 13th, 2014

Singapore Patents Rules as amended by S 739 of 2014 ENTRY INTO FORCE: Nov 13th, 2014 Singapore Patents Rules as amended by S 739 of 2014 ENTRY INTO FORCE: Nov 13th, 2014 TABLE OF CONTENTS PRELIMINARY 1. Citation 2. Definitions 2A. Definitions of examination, search and supplementary examination

More information

Global Access to Medicines Program Compiled by Stephanie Rosenberg. December 2, This chart compares provisions from the following texts:

Global Access to Medicines Program Compiled by Stephanie Rosenberg. December 2, This chart compares provisions from the following texts: Comparative chart of patent and data provisions in the TRIPS, Free Trade s between Trans-Pacific negotiating countries and the U.S., and the U.S. proposal to the Trans-Pacific This chart compares provisions

More information

LAWS OF MALAWI PATENTS CHAPTER 49:02 CURRENT PAGES

LAWS OF MALAWI PATENTS CHAPTER 49:02 CURRENT PAGES PATENTS CHAPTER 49:02 PAGE CURRENT PAGES L.R.O. 1 4 1/1986 5 10 1/1968 11 12 1/1986 13 64 1/1968 65 68 1/1970 69-86 1/1968 87 88 1/1970 89 90 1/1993 91 108 1/1968 109 112 1/1993 112a 1/1993 113 114 1/1968

More information

VECTRA FITNESS, INC., TNWK CORPORATION, (formerly known as Pacific Fitness Corporation),

VECTRA FITNESS, INC., TNWK CORPORATION, (formerly known as Pacific Fitness Corporation), United States Court of Appeals for the Federal Circuit 98-1192 Plaintiff-Appellant, VECTRA FITNESS, INC., v. TNWK CORPORATION, Defendant-Appellee. (formerly known as Pacific Fitness Corporation), Ramsey

More information

GUIDELINES FOR EXAMINATION OF REGISTERED COMMUNITY DESIGNS EUROPEAN UNION INTELLECTUAL PROPERTY OFFICE (EUIPO) REGISTERED COMMUNITY DESIGNS

GUIDELINES FOR EXAMINATION OF REGISTERED COMMUNITY DESIGNS EUROPEAN UNION INTELLECTUAL PROPERTY OFFICE (EUIPO) REGISTERED COMMUNITY DESIGNS GUIDELINES FOR EXAMINATION OF REGISTERED COMMUNITY DESIGNS EUROPEAN UNION INTELLECTUAL PROPERTY OFFICE (EUIPO) REGISTERED COMMUNITY DESIGNS EXAMINATION OF DESIGN INVALIDITY APPLICATIONS Guidelines for

More information

Note: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail. Part III Patentability

Note: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail. Part III Patentability Note: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail. Part III Patent Act (Requirements for ) Article 29(1) Any person

More information

Notwithstanding Article 29, any invention that is liable to injure public order, morality or public health shall not be patented (Article 32).

Notwithstanding Article 29, any invention that is liable to injure public order, morality or public health shall not be patented (Article 32). Japan Patent Office (JPO) Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 2 Section 3: Experimental use and/or scientific research... 3 Section 4: Preparation of medicines...

More information

Navigating through the Obviousness-Type Double Patenting Minefield Landslide Vol. 10, No. 3 January/February 2018

Navigating through the Obviousness-Type Double Patenting Minefield Landslide Vol. 10, No. 3 January/February 2018 Navigating through the Obviousness-Type Double Patenting Minefield Landslide Vol. 10, No. 3 January/February 2018 Elizabeth A Doherty, PhD 925.231.1991 elizabeth.doherty@mcneillbaur.com Amelia Feulner

More information

The patentability criteria for inventive step I nonobviousness. The Groups are invited to answer the following questions under their national laws:

The patentability criteria for inventive step I nonobviousness. The Groups are invited to answer the following questions under their national laws: Question Q217 National Group: United States Title: The patentability criteria for inventive step I nonobviousness Contributors: Marc V. Richards Chair Alan Kasper Drew Meunier Joshua Goldberg Dan Altman

More information